Advertisement

Drug Delivery and Translational Research

, Volume 9, Issue 5, pp 906–919 | Cite as

Protective effect of surface-modified berberine nanoparticles against LPS-induced neurodegenerative changes: a preclinical study

  • Salma A. Soudi
  • Mohamed I. NounouEmail author
  • Salah A. Sheweita
  • Doaa A. Ghareeb
  • Layla K. Younis
  • Labiba K. El-Khordagui
Original Article
  • 385 Downloads

Abstract

Berberine (BBR) exerts documented protection against neurodegenerative disorders. However, data on the effect of nano-encapsulation on the neuroprotective effect of BBR are lacking. We investigated the effect of BBR loading into chitosan (CS) nanoparticles (NPs) and their surface modification with Tween 80 (T80), polyethylene glycol 4000 (PEG), and miltefosine (MFS) against lipopolysaccharide (LPS)-induced neurodegenerative changes in addition to hepatotoxicity in rats. BBR-NPs were prepared by ionic gelation and characterized for morphology by transmission electron microscopy (TEM), colloidal properties, and entrapment efficiency (EE%). The neuroprotective and hepatoprotective effects of a 14-day pretreatment with four BBR-NPs formulations (4 mg/kg BBR/day) by intraperitoneal (i.p.) injection were challenged by a single i.p. 4 mg/kg dose of LPS on the fifteenth day. Neuroprotective efficacy and potential toxicity of BBR-NPs relative to BBR solution were assessed biochemically and histopathologically. One-way ANOVA followed by Tukey’s comparison test was used for statistical analysis. CS nano-encapsulation and surface modification of BBR-NPs altered the neuroprotective and hepatoprotective effects of BBR depending on the physicochemical and/or biological effects of BBR, CS, coating materials, and NP-related features. Similar to the prophylactic and treatment efficacy of NPs for brain delivery, safety of these nanostructures and their individual formulation components warrants due research attention.

Keywords

Berberine Chitosan Tween 80 Polyethylene glycol (PEG) Miltefosine Lipopolysaccharide Nanoparticles Neuroprotection 

Abbreviations

AChE

Acetylcholine esterase

Aβ 1-42

Amyloid beta 1-42

ALT

Alanine aminotransferase

AST

Aspartate aminotransferase

CS

Chitosan

GSH

Reduced glutathione

LPS

Lipopolysaccharide

MFS

Miltefosine

NO

Total nitric oxide

NPs

Nanoparticles

PEG

Polyethylene glycol 4000

TBARS

Thiobarbituric acid-reactive substances

TEM

Transmission electron microscopy

TNF-α

Tumor necrosis factor-alpha

T80

Tween 80

Notes

Availability of data and materials

Not applicable.

Authors’ contributions

SAS: data acquisition and contribution to data interpretation and manuscript drafting. MIN and LKE: Contribution to the study design, data analysis, and interpretation and major drafting and revision of the manuscript; SAS and DAG: contribution to the study design and biochemical assessments; LY: histopathological examination and data interpretation. SAS and LKE: responsibility for the integrity of the work. All authors read and approved the final manuscript.

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.

Ethics approval

Animal handling and experimental protocols were approved by the Research Ethics Committee of the Medical Research Institute, Alexandria University (Alexandria, Egypt) and complied with the Guide for the Care and Use of Laboratory Animals issued by the National Research Council (US) Institute for Laboratory Animal Research (ILAR, 1996).

Consent for publication

Not applicable.

References

  1. 1.
    Kulkarni SK, Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res: PTR. 2010;24(3):317–24.  https://doi.org/10.1002/ptr.2968.CrossRefPubMedGoogle Scholar
  2. 2.
    Poupot R, Bergozza D, Fruchon S. Nanoparticle-based strategies to treat neuro-inflammation. Materials. 2018;11(2).  https://doi.org/10.3390/ma11020270.
  3. 3.
    Yadav M, Parle M, Sharma N, Dhingra S, Raina N, Jindal DK. Brain targeted oral delivery of doxycycline hydrochloride encapsulated tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice. Drug delivery. 2017;24(1):1429–40.  https://doi.org/10.1080/10717544.2017.1377315.CrossRefPubMedGoogle Scholar
  4. 4.
    Ishak RAH, Mostafa NM, Kamel AO. Stealth lipid polymer hybrid nanoparticles loaded with rutin for effective brain delivery—comparative study with the gold standard (tween 80): optimization, characterization and biodistribution. Drug delivery. 2017;24(1):1874–90.  https://doi.org/10.1080/10717544.2017.1410263.CrossRefPubMedGoogle Scholar
  5. 5.
    McNeeley KM, Karathanasis E, Annapragada AV, Bellamkonda RV. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. Biomaterials. 2009;30(23–24):3986–95.  https://doi.org/10.1016/j.biomaterials.2009.04.012.CrossRefPubMedGoogle Scholar
  6. 6.
    Lohan S, Raza K, Mehta SK, Bhatti GK, Saini S, Singh B. Anti-Alzheimer's potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence. Int J Pharm. 2017;530(1–2):263–78.  https://doi.org/10.1016/j.ijpharm.2017.07.080.CrossRefPubMedGoogle Scholar
  7. 7.
    Mirhadi E, Rezaee M, Malaekeh-Nikouei B. Nano strategies for berberine delivery, a natural alkaloid of berberis. Biomed Pharmacother. 2018;104:465–73.  https://doi.org/10.1016/j.biopha.2018.05.067.CrossRefPubMedGoogle Scholar
  8. 8.
    Yu F, Ao M, Zheng X, Li N, Xia J, Li Y, et al. PEG-lipid-PLGA hybrid nanoparticles loaded with berberine-phospholipid complex to facilitate the oral delivery efficiency. Drug delivery. 2017;24(1):825–33.  https://doi.org/10.1080/10717544.2017.1321062.CrossRefPubMedGoogle Scholar
  9. 9.
    Sahibzada MUK, Sadiq A, Faidah HS, Khurram M, Amin MU, Haseeb A, et al. Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity. Drug Des Devel Ther. 2018;12:303–12.  https://doi.org/10.2147/DDDT.S156123.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang Y, Wen B, Yu H, Ding D, Zhang J, Zhang Y, et al. Berberine hydrochloride-loaded chitosan nanoparticles effectively targets and suppresses human nasopharyngeal carcinoma. J Biomed Nanotechnol. 2018;14(8):1486–95.  https://doi.org/10.1166/jbn.2018.2596.CrossRefPubMedGoogle Scholar
  11. 11.
    Xie D, Xu Y, Jing W, Juxiang Z, Hailun L, Yu H, et al. Berberine nanoparticles protects tubular epithelial cells from renal ischemia-reperfusion injury. Oncotarget. 2017;8(15):24154–62.  https://doi.org/10.18632/oncotarget.16530.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Sahin A, Yoyen-Ermis D, Caban-Toktas S, Horzum U, Aktas Y, Couvreur P, et al. Evaluation of brain-targeted chitosan nanoparticles through blood-brain barrier cerebral microvessel endothelial cells. J Microencapsul. 2017;34(7):659–66.  https://doi.org/10.1080/02652048.2017.1375039.CrossRefPubMedGoogle Scholar
  13. 13.
    Roy SL, Atkins JT, Gennuso R, Kofos D, Sriram RR, Dorlo TP, et al. Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain. Parasitol Res. 2015;114(12):4431–9.  https://doi.org/10.1007/s00436-015-4684-8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhou Y, Liu SQ, Peng H, Yu L, He B, Zhao Q. In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis. Int Immunopharmacol. 2015;28(1):34–43.  https://doi.org/10.1016/j.intimp.2015.05.014.CrossRefPubMedGoogle Scholar
  15. 15.
    Tahara K, Miyazaki Y, Kawashima Y, Kreuter J, Yamamoto H. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration. Eur J Pharm Biopharm. 2011;77(1):84–8.  https://doi.org/10.1016/j.ejpb.2010.11.002.CrossRefPubMedGoogle Scholar
  16. 16.
    Tsai Pi, Tsai TH. Simultaneous determination of berberine in rat blood, liver and bile using microdialysis coupled to highperformance liquid chromatography. J Chromatogr A. 2002;961(1):125–30.  https://doi.org/10.1016/s0021-9673(02)00365-5.
  17. 17.
    Lee B, Sur B, Shim I, Lee H, Hahm DH. Phellodendron amurense and its major alkaloid compound, berberine ameliorates scopolamine-induced neuronal impairment and memory dysfunction in rats. Korean J Physiol Pharmacol. 2012;16(2):79–89.  https://doi.org/10.4196/kjpp.2012.16.2.79.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Abdel-Latif MS, Hegazy A, Khalil S, Ghareeb DA. Prophylactic effect of herbal extracts on LPS-induced inflammatory response in rat hepatocytes. Int J Phytomed. 2017;9(1):20–8.Google Scholar
  19. 19.
    Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961;7:88–95.CrossRefGoogle Scholar
  20. 20.
    Wills ED. Mechanisms of lipid peroxide formation in tissues. Role of metals and Haematin proteins in the catalysis of the oxidation unsaturated fatty acids. Biochim Biophys Acta. 1965;98:238–51.CrossRefGoogle Scholar
  21. 21.
    Parihar M, Javeri T, Hemnani T, Dubey A, Prakash P. Responses of superoxide dismutase, glutathione peroxidase and reduced glutathione antioxidant defenses in gills of the freshwater catfish (Heteropneustes fossilis) to short-term elevated temperature. J Therm Biol. 1997;22(2):151–6.CrossRefGoogle Scholar
  22. 22.
    Hjelm M, Verdier C. A methodological study of the enzymatic determination of glucose in blood. Scand J Clin Lab Invest. 1963;15(4):415–28.CrossRefGoogle Scholar
  23. 23.
    Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide Biol Chem. 2001;5(1):62–71.  https://doi.org/10.1006/niox.2000.0319.CrossRefGoogle Scholar
  24. 24.
    Layne E. [73] Spectrophotometric and turbidimetric methods for measuring proteins. Methods Enzymol. 1957;3:447–54.CrossRefGoogle Scholar
  25. 25.
    Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta. 1971;31(1):87–96.CrossRefGoogle Scholar
  26. 26.
    Saraiva C, Praca C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Controll Release. 2016;235:34–47.  https://doi.org/10.1016/j.jconrel.2016.05.044.CrossRefGoogle Scholar
  27. 27.
    Patel VR, Agrawal YK. Nanosuspension: an approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011;2(2):81–7.  https://doi.org/10.4103/2231-4040.82950.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Pandian S, Jeevanesan V, Ponnusamy C, Natesan S. RES-loaded pegylated CS NPs: for efficient ocular delivery. IET nanobiotechnology. 2017;11(1):32–9.  https://doi.org/10.1049/iet-nbt.2016.0069.CrossRefPubMedGoogle Scholar
  29. 29.
    Papagiannaros A, Hatziantoniou S, Dimas K, Papaioannou GT, Demetzos C. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. Biomed Pharmacother. 2006;60(1):36–42.  https://doi.org/10.1016/j.biopha.2005.09.001.CrossRefPubMedGoogle Scholar
  30. 30.
    Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28(1):1–13.  https://doi.org/10.1081/DDC-120001481.CrossRefPubMedGoogle Scholar
  31. 31.
    Cruz LJ, Tacken PJ, Fokkink R, Figdor CG. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells. Biomaterials. 2011;32(28):6791–803.  https://doi.org/10.1016/j.biomaterials.2011.04.082.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. Front Aging Neurosci. 2018;10:42.  https://doi.org/10.3389/fnagi.2018.00042.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Magalingam KB, Radhakrishnan A, Ping NS, Haleagrahara N. Current concepts of neurodegenerative mechanisms in Alzheimer’s disease. Biomed Res Int. 2018;2018:3740461–12.  https://doi.org/10.1155/2018/3740461.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Pangestuti R, Kim SK. Neuroprotective properties of chitosan and its derivatives. Mar Drugs. 2010;8(7):2117–28.  https://doi.org/10.3390/md8072117.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Jang J, Jung Y, Seo SJ, Kim SM, Shim YJ, Cho SH, et al. Berberine activates AMPK to suppress proteolytic processing, nuclear translocation and target DNA binding of SREBP-1c in 3T3-L1 adipocytes. Mol Med Rep. 2017;15(6):4139–47.  https://doi.org/10.3892/mmr.2017.6513.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Brusq JM, Ancellin N, Grondin P, Guillard R, Martin S, Saintillan Y, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006;47(6):1281–8.  https://doi.org/10.1194/jlr.M600020-JLR200.CrossRefPubMedGoogle Scholar
  37. 37.
    Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes. 2003;27(Suppl 3):S53–5.  https://doi.org/10.1038/sj.ijo.0802502.CrossRefGoogle Scholar
  38. 38.
    Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009;89(3):1025–78.  https://doi.org/10.1152/physrev.00011.2008.CrossRefPubMedGoogle Scholar
  39. 39.
    Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 2005;66(3):562–73.  https://doi.org/10.1016/j.cardiores.2005.01.026.CrossRefGoogle Scholar
  40. 40.
    Lira VA, Brown DL, Lira AK, Kavazis AN, Soltow QA, Zeanah EH, et al. Nitric oxide and AMPK cooperatively regulate PGC-1 in skeletal muscle cells. J Physiol. 2010;588(Pt 18):3551–66.  https://doi.org/10.1113/jphysiol.2010.194035.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Lv Q, Zhen Q, Liu L, Gao R, Yang S, Zhou H, et al. AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells. Life Sci. 2015;131:23–9.  https://doi.org/10.1016/j.lfs.2015.03.003.CrossRefPubMedGoogle Scholar
  42. 42.
    Ghareeb DA, Khalil S, Hafez HS, Bajorath J, Ahmed HE, Sarhan E, et al. Berberine reduces neurotoxicity related to nonalcoholic steatohepatitis in rats. Evidence-based Complement Alternat Med: eCAM. 2015;2015:361847–13.  https://doi.org/10.1155/2015/361847.CrossRefGoogle Scholar
  43. 43.
    Ouyang QQ, Zhao S, Li SD, Song C. Application of chitosan, chitooligosaccharide, and their derivatives in the treatment of Alzheimer’s disease. Mar Drugs. 2017;15(11).  https://doi.org/10.3390/md15110322.
  44. 44.
    Patil GB, Surana SJ. Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies. Artificial Cells Nanomed Biotechnol. 2017;45(3):505–14.  https://doi.org/10.3109/21691401.2016.1163713.CrossRefGoogle Scholar
  45. 45.
    Pachioni Jde A, Magalhaes JG, Lima EJ, Bueno Lde M, Barbosa JF, de Sa MM, et al. Alkylphospholipids—a promising class of chemotherapeutic agents with a broad pharmacological spectrum. J Pharm Pharm Sci. 2013;16(5):742–59.CrossRefGoogle Scholar
  46. 46.
    Khallaf WAI, Messiha BAS, Abo-Youssef AMH, El-Sayed NS. Protective effects of telmisartan and tempol on lipopolysaccharide-induced cognitive impairment, neuroinflammation, and amyloidogenesis: possible role of brain-derived neurotrophic factor. Can J Physiol Pharmacol. 2017;95(7):850–60.  https://doi.org/10.1139/cjpp-2017-0042.CrossRefPubMedGoogle Scholar
  47. 47.
    Cai Z, Wang C, He W, Chen Y. Berberine alleviates amyloid-beta pathology in the brain of APP/PS1 transgenic mice via inhibiting beta/gamma-secretases activity and enhancing alpha-secretases. Curr Alzheimer Res. 2018;15:1045–52.  https://doi.org/10.2174/1567205015666180702105740.CrossRefPubMedGoogle Scholar
  48. 48.
    Brambilla D, Verpillot R, Le Droumaguet B, Nicolas J, Taverna M, Kona J, et al. PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer’s disease. ACS Nano. 2012;6(7):5897–908.  https://doi.org/10.1021/nn300489k.CrossRefPubMedGoogle Scholar
  49. 49.
    Al-Amin MM, Choudhury MFR, Chowdhury AS, Chowdhury TR, Jain P, Kazi M, et al. Pretreatment with risperidone ameliorates systemic LPS-induced oxidative stress in the cortex and hippocampus. Front Neurosci. 2018;12:384.  https://doi.org/10.3389/fnins.2018.00384.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Cobley JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490–503.  https://doi.org/10.1016/j.redox.2018.01.008.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Hussien HM, Abd-Elmegied A, Ghareeb DA, Hafez HS, Ahmed HEA, El-Moneam NA. Neuroprotective effect of berberine against environmental heavy metals-induced neurotoxicity and Alzheimer’s-like disease in rats. Food Chem Toxicol. 2018;111:432–44.  https://doi.org/10.1016/j.fct.2017.11.025.CrossRefPubMedGoogle Scholar
  52. 52.
    Perez-Roses R, Risco E, Vila R, Penalver P, Canigueral S. Antioxidant activity of Tween-20 and Tween-80 evaluated through different in-vitro tests. J Pharm Pharmacol. 2015;67(5):666–72.  https://doi.org/10.1111/jphp.12369.CrossRefPubMedGoogle Scholar
  53. 53.
    Liu-Snyder P, Logan MP, Shi R, Smith DT, Borgens RB. Neuroprotection from secondary injury by polyethylene glycol requires its internalization. J Exp Biol. 2007;210(Pt 8):1455–62.  https://doi.org/10.1242/jeb.02756.CrossRefPubMedGoogle Scholar
  54. 54.
    Yuan ZY, Hu YL, Gao JQ. Brain localization and neurotoxicity evaluation of polysorbate 80-modified chitosan nanoparticles in rats. PLoS One. 2015;10(8):e0134722.  https://doi.org/10.1371/journal.pone.0134722.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Pocernich CB, Butterfield DA. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta. 2012;1822(5):625–30.  https://doi.org/10.1016/j.bbadis.2011.10.003.CrossRefPubMedGoogle Scholar
  56. 56.
    Al-Saeedan AS, Gautam V, Ansari MN, Singh M, Yadav RK, Rawat JK, et al. Revisiting the systemic lipopolysaccharide mediated neuroinflammation: appraising the effect of l-cysteine mediated hydrogen sulphide on it. Saudi Pharm J. 2018;26(4):520–7.  https://doi.org/10.1016/j.jsps.2018.02.004.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    He W, Wang C, Chen Y, He Y, Cai Z. Berberine attenuates cognitive impairment and ameliorates tau hyperphosphorylation by limiting the self-perpetuating pathogenic cycle between NF-kappaB signaling, oxidative stress and neuroinflammation. Pharmacol Rep: PR. 2017;69(6):1341–8.  https://doi.org/10.1016/j.pharep.2017.06.006.CrossRefPubMedGoogle Scholar
  58. 58.
    Banks WA, Dohgu S, Lynch JL, Fleegal-DeMotta MA, Erickson MA, Nakaoke R, et al. Nitric oxide isoenzymes regulate lipopolysaccharide-enhanced insulin transport across the blood-brain barrier. Endocrinology. 2008;149(4):1514–23.  https://doi.org/10.1210/en.2007-1091.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Cheng Z, Pang T, Gu M, Gao A-H, Xie C-M, Li J-Y, et al. Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim Biophys Acta (BBA)-Gen Subj. 2006;1760(11):1682–9.CrossRefGoogle Scholar
  60. 60.
    Kao CH, Hsiang CY, Ho TY. Assessment of chitosan-affected metabolic response by peroxisome proliferator-activated receptor bioluminescent imaging-guided transcriptomic analysis. PLoS One. 2012;7(4):e34969.  https://doi.org/10.1371/journal.pone.0034969.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Kong W-J, Zhang H, Song D-Q, Xue R, Zhao W, Wei J, et al. Berberine reduces insulin resistance through protein kinase C–dependent up-regulation of insulin receptor expression. Metabolism. 2009;58(1):109–19.CrossRefGoogle Scholar
  62. 62.
    Verma N, Dey C. The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro. Diabetologia. 2006;49(7):1656–60.CrossRefGoogle Scholar
  63. 63.
    Hui B, Zhang L, Zhou Q, Hui L. Pristimerin inhibits LPS-triggered neurotoxicity in BV-2 microglia cells through modulating IRAK1/TRAF6/TAK1-mediated NF-kappaB and AP-1 signaling pathways in vitro. Neurotox Res. 2018;33(2):268–83.  https://doi.org/10.1007/s12640-017-9837-3.CrossRefPubMedGoogle Scholar
  64. 64.
    Zhang H, Shan Y, Wu Y, Xu C, Yu X, Zhao J, et al. Berberine suppresses LPS-induced inflammation through modulating Sirt1/NF-kappaB signaling pathway in RAW264.7 cells. Int Immunopharmacol. 2017;52:93–100.  https://doi.org/10.1016/j.intimp.2017.08.032.CrossRefPubMedGoogle Scholar
  65. 65.
    Uğurel SS, Kuşçu N, Özenci ÇÇ, Dalaklıoğlu S, Taşatargil A. Resveratrol prevented lipopolysaccharide-induced endothelial dysfunction in rat thoracic aorta through increased eNOS expression. Balkan Med J. 2016;33(2):138–43.CrossRefGoogle Scholar
  66. 66.
    Zeng J, Zhao H, Liu Z, Zhang W, Huang Y. Lipopolysaccharide induces subacute cerebral microhemorrhages with involvement of nitric oxide synthase in rats. J Stroke Cerebrovasc Dis. 2018;27(7):1905–13.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.02.044.CrossRefPubMedGoogle Scholar
  67. 67.
    Zhu F, Qian C. Berberine chloride can ameliorate the spatial memory impairment and increase the expression of interleukin-1beta and inducible nitric oxide synthase in the rat model of Alzheimer's disease. BMC Neurosci. 2006;7(1):1.CrossRefGoogle Scholar
  68. 68.
    Dawson TM, Dawson VL. Nitric oxide signaling in neurodegeneration and cell death. Adv Pharmacol. 2018;82:57–83.  https://doi.org/10.1016/bs.apha.2017.09.003.CrossRefPubMedGoogle Scholar
  69. 69.
    Murray CL, Skelly DT, Cunningham C. Exacerbation of CNS inflammation and neurodegeneration by systemic LPS treatment is independent of circulating IL-1beta and IL-6. J Neuroinflammation. 2011;8:50.  https://doi.org/10.1186/1742-2094-8-50.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Noh H, Jeon J, Seo H. Systemic injection of LPS induces region-specific neuroinflammation and mitochondrial dysfunction in normal mouse brain. Neurochem Int. 2014;69:35–40.  https://doi.org/10.1016/j.neuint.2014.02.008.CrossRefGoogle Scholar
  71. 71.
    Zhong J, Deaciuc IV, Burikhanov R, de Villiers WJ. Lipopolysaccharide-induced liver apoptosis is increased in interleukin-10 knockout mice. Biochim Biophys Acta. 2006;1762(4):468–77.  https://doi.org/10.1016/j.bbadis.2005.12.012.CrossRefPubMedGoogle Scholar
  72. 72.
    Jeschke MG, Rensing H, Klein D, Schubert T, Mautes AE, Bolder U, et al. Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J Hepatol. 2005;42(6):870–9.  https://doi.org/10.1016/j.jhep.2004.12.036.CrossRefPubMedGoogle Scholar
  73. 73.
    Janbaz KH, Gilani AH. Studies on preventive and curative effects of berberine on chemical-induced hepatotoxicity in rodents. Fitoterapia. 2000;71(1):25–33.CrossRefGoogle Scholar
  74. 74.
    Mehrzadi S, Fatemi I, Esmaeilizadeh M, Ghaznavi H, Kalantar H, Goudarzi M. Hepatoprotective effect of berberine against methotrexate induced liver toxicity in rats. Biomed Pharmacother. 2018;97:233–9.  https://doi.org/10.1016/j.biopha.2017.10.113.CrossRefPubMedGoogle Scholar
  75. 75.
    Yang J, Ma XJ, Li L, Wang L, Chen YG, Liu J, et al. Berberine ameliorates non-alcoholic steatohepatitis in ApoE(−/−) mice. Exp Ther Med. 2017;14(5):4134–40.  https://doi.org/10.3892/etm.2017.5051.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    El-Denshary E, Aljawish A, El-Nekeety A, Hassan N, Saleh R, Rihn B, et al. Possible synergistic effect and antioxidant properties of chitosan nanoparticles and quercetin against carbon tetrachloride-induce hepatotoxicity in rats. Soft Nanosci Lett. 2015;5:36–51.CrossRefGoogle Scholar
  77. 77.
    Chen CC, Wu CC. Acute hepatotoxicity of intravenous amiodarone: case report and review of the literature. Am J Ther. 2016;23(1):e260–3.  https://doi.org/10.1097/MJT.0000000000000149.CrossRefPubMedGoogle Scholar
  78. 78.
    Khan AY, Suresh KG. Natural isoquinoline alkaloids: binding aspects to functional proteins, serum albumins, hemoglobin, and lysozyme. Biophys Rev. 2015;7(4):407–20.  https://doi.org/10.1007/s12551-015-0183-5.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Bekale L, Agudelo D, Tajmir-Riahi HA. Effect of polymer molecular weight on chitosan-protein interaction. Colloids Surf B: Biointerfaces. 2015;125:309–17.  https://doi.org/10.1016/j.colsurfb.2014.11.037.CrossRefPubMedGoogle Scholar
  80. 80.
    Comoglu T, Arisoy S, Akkus ZB. Nanocarriers for effective brain drug delivery. Curr Top Med Chem. 2017;17(13):1490–506.  https://doi.org/10.2174/1568026616666161222101355.CrossRefPubMedGoogle Scholar

Copyright information

© Controlled Release Society 2019

Authors and Affiliations

  1. 1.Department of Biotechnology, Institute of Graduate Studies and ResearchAlexandria UniversityAlexandriaEgypt
  2. 2.Department of Pharmaceutical Sciences, School of Pharmacy and Physician Assistant Studies (SOPPAS)University of Saint Joseph (USJ)HartfordUSA
  3. 3.Department of Clinical Biochemistry, Faculty of MedicineKing Khalid UniversityAbhaKingdom of Saudi Arabia
  4. 4.Biological screening and preclinical trial laboratory, Department of Biochemistry, Faculty of ScienceAlexandria UniversityAlexandriaEgypt
  5. 5.Pharmaceutical and Fermentation Industries Development CenterCity for Scientific Research and Technology ApplicationsAlexandriaEgypt
  6. 6.Department of Pathology, Faculty of MedicineAlexandria UniversityAlexandriaEgypt
  7. 7.Department of Pharmaceutics, Faculty of PharmacyAlexandria UniversityAlexandriaEgypt

Personalised recommendations